Macrophages as novel target cells for erythropoietin

Haematologica

Volumn 95, Issue 11, 2010, Pages 1823-1831

  Lifshitz, Lilach ^a,b   Tabak, Galit ^a   Gassmann, Max ^c   Mittelman, Moshe ^b   Neumann, Drorit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Erythropoietin receptor; Macrophages; Pro inflammation; Signal transducer and activator of transcription (STAT)

Indexed keywords

B7 ANTIGEN; CD11B ANTIGEN; CELL MARKER; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE; RECOMBINANT ERYTHROPOIETIN; STAT1 PROTEIN; STAT5 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HORMONE ACTION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PHAGOCYTOSIS; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN CELL; TARGET CELL; UPREGULATION; WILD TYPE;

ANIMALS; ANTIGENS, CD11B; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; BONE MARROW CELLS; CELLS, CULTURED; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-10; INTERLEUKIN-12; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NF-KAPPA B; PHAGOCYTOSIS; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; UP-REGULATION;

EID: 78149248400     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.025015     Document Type: Article

References (35)

1. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol. 2008;141(1):14-31.
2. Mittelman M, Zeidman A, Fradin Z, Magazanik A, Lewinski UH, Cohen A. Recombinant human erythropoietin in the treatment of multiple myeloma-associated anemia. Acta Haematol. 1997;98(4):204-10.
3. Prutchi-Sagiv S, Golishevsky N, Oster HS, Katz O, Cohen A, Naparstek E, et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease? Br J Haematol. 2006;135(5):660-72.
4. Mittelman M, Neumann D, Peled A, Kanter P, Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc Natl Acad Sci USA. 2001;98(9):5181-6.
5. Katz O, Barzilay E, Skaat A, Herman A, Mittelman M, Neumann D. Erythropoietin induced tumour mass reduction in murine lymphoproliferative models. Acta Haematol. 2005;114(3):177-9.
6. Katz O, Gil L, Lifshitz L, Prutchi-Sagiv S, Gassmann M, Mittelman M, et al. Erythropoietin enhances immune responses in mice. Eur J Immunol. 2007;37(6):1584-93.
7. Prutchi Sagiv S, Lifshitz L, Orkin R, Mittelman M, Neumann D. Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator? Exp Hematol. 2008;36(12):1682-90.
8. Lifshitz L, Prutchi-Sagiv S, Avneon M, Gassmann M, Mittelman M, Neumann D. Non-erythroid activities of erythropoietin: Functional effects on murine dendritic cells. Mol Immunol. 2009;46(4):713-21.
9. Hume DA. The mononuclear phagocyte system. Curr Opin Immunol. 2006;18(1):49-53.
10. McCormack JM, Moore SC, Gatewood JW, Walker WS. Mouse splenic macrophage cell lines with different antigen-presenting activities for CD4+ helper T cell subsets and allogeneic CD8+ T cells. Cell Immunol. 1992;145(2):359-71.
11. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. The mononuclear phagocyte system revisited. J Leukoc Biol. 2002;72(4):621-7.
12. Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C, Wagner K, et al. Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA. 2000;97(21): 11609-13.
13. Boltz-Nitulescu G, Wiltschke C, Holzinger C, Fellinger A, Scheiner O, Gessl A, et al. Differentiation of rat bone marrow cells into macrophages under the influence of mouse L929 cell supernatant. J Leukoc Biol. 1987;41(1):83-91.
14. Cohen J, Oren-Young L, Klingmuller U, Neumann D. Protein tyrosine phosphatase 1B participates in the down-regulation of erythropoietin receptor signalling. Biochem J. 2004;377(Pt 2):517-24.
15. Takahashi K, Naito M, Takeya M. Development and heterogeneity of macrophages and their related cells through their differentiation pathways. Pathol Int. 1996;46(7):473-85.
16. Leenen PJ, de Bruijn MF, Voerman JS, Campbell PA, van Ewijk W. Markers of mouse macrophage development detected by monoclonal antibodies. J Immunol Methods. 1994;174(1-2):5-19.
17. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G, Meerschaut S, Beschin A, Raes G, et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology. 2006;211(6-8):487-501.
18. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated by erythropoietin. Trends Cell Biol. 2005;15(3):146-55.
19. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol. 2008;214(2):161-78.
20. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol. 2009;27:669-92.
21. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5(12):953-64.
22. Hume DA. Macrophages as APC and the dendritic cell myth. J Immunol. 2008; 181(9):5829-35.
23. Ribatti D, Crivellato E, Nico B, Guidolin D, Gassmann M, Djonov V. Mast cells and macrophages in duodenal mucosa of mice overexpressing erythropoietin. J Anat. 2009;215(5):548-54.
24. Bogdanova A, Mihov D, Lutz H, Saam B, Gassmann M, Vogel J. Enhanced erythrophagocytosis in polycythemic mice overexpressing erythropoietin. Blood. 2007;110 (2):762-9.
25. Haroon ZA, Amin K, Jiang X, Arcasoy MO. A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol. 2003;163(3):993-1000.
26. Broudy VC, Lin N, Brice M, Nakamoto B, Papayannopoulou T. Erythropoietin receptor characteristics on primary human erythroid cells. Blood. 1991;77(12):2583-90.
27. Menon MP, Fang J, Wojchowski DM. Core erythropoietin receptor signals for late erythroblast development. Blood. 2006;107(7): 2662-72.
28. Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003;19(6):903-12.
29. Hu X, Chakravarty SD, Ivashkiv LB. Regulation of interferon and Toll-like receptor signaling during macrophage activation by opposing feedforward and feedback inhibition mechanisms. Immunol Rev. 2008;226:41-56.
30. Iles KE, Dickinson DA, Watanabe N, Iwamoto T, Forman HJ. AP-1 activation through endogenous H(2)O(2) generation by alveolar macrophages. Free Radic Biol Med. 2002;32(12):1304-13.
31. Farrell F, Lee A. The erythropoietin receptor and its expression in tumor cells and other tissues. Oncologist. 2004;9 (Suppl 5):18-30.
32. Marzo F, Lavorgna A, Coluzzi G, Santucci E, Tarantino F, Rio T, et al. Erythropoietin in heart and vessels: focus on transcription and signalling pathways. J Thromb Thrombolysis. 2008;26(3):183-7.
33. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol. 2008;67(1):39-61.
34. Longmore GD. Do cancer cells express functional erythropoietin receptors? N Engl J Med. 2007;356(24):2447.
35. Benayahu D, Fried A, Efraty M, Robey PG, Wientroub S. Bone marrow interface: preferential attachment of an osteoblastic marrow stromal cell line. J Cell Biochem. 1995;59(2):151-60.